Pf Prism Cv Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PF PRISM CV, and when can generic versions of PF PRISM CV drugs launch?
PF PRISM CV has sixteen approved drugs.
There are twenty-nine US patents protecting PF PRISM CV drugs.
There are six hundred and twelve patent family members on PF PRISM CV drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.
Summary for Pf Prism Cv
International Patents: | 612 |
US Patents: | 29 |
Tradenames: | 11 |
Ingredients: | 11 |
NDAs: | 16 |
Drugs and US Patents for Pf Prism Cv
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-001 | Sep 4, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-001 | Sep 26, 2023 | RX | Yes | No | 7,767,678*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | TORISEL | temsirolimus | SOLUTION;INTRAVENOUS | 022088-001 | May 30, 2007 | AP | RX | Yes | Yes | 8,722,700*PED | ⤷ Try a Trial | ⤷ Try a Trial | |||
Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-003 | Sep 7, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-001 | Sep 4, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pf Prism Cv
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-002 | Jan 27, 2012 | 7,141,581 | ⤷ Try a Trial |
Pf Prism Cv | VFEND | voriconazole | INJECTABLE;INTRAVENOUS | 021267-001 | May 24, 2002 | 5,376,645 | ⤷ Try a Trial |
Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-001 | Nov 6, 2012 | 7,301,023 | ⤷ Try a Trial |
Pf Prism Cv | VFEND | voriconazole | TABLET;ORAL | 021266-002 | May 24, 2002 | 5,567,817 | ⤷ Try a Trial |
Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-004 | Jan 25, 2010 | 5,100,899*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PF PRISM CV drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 1 mg and 2 mg | ➤ Subscribe | 2009-12-17 |
➤ Subscribe | Extended-release Tablets | 50 mg and 100 mg | ➤ Subscribe | 2012-02-29 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-10 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Tablets | 100mg and 500mg | ➤ Subscribe | 2016-09-06 |
➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2008-09-12 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2010-10-08 |
➤ Subscribe | Injection | 25 mg/mL, 1.8 mL vial | ➤ Subscribe | 2011-05-25 |
➤ Subscribe | Tablets | 0.5 mg | ➤ Subscribe | 2010-08-25 |
➤ Subscribe | Extended-release Tablets | 25 mg | ➤ Subscribe | 2015-05-08 |
➤ Subscribe | Tablets | 1 mg and 5 mg | ➤ Subscribe | 2018-02-23 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2018-10-15 |
➤ Subscribe | Tablets | 50 mg and 200 mg | ➤ Subscribe | 2008-04-14 |
➤ Subscribe | For Injection | 50 mg per vial | ➤ Subscribe | 2009-06-15 |
International Patents for Pf Prism Cv Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 0142246 | ⤷ Try a Trial |
Hungary | E029052 | ⤷ Try a Trial |
Serbia | 20050708 | ⤷ Try a Trial |
Mexico | 2017016324 | ⤷ Try a Trial |
New Zealand | 516676 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pf Prism Cv Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1786785 | 2013/009 | Ireland | ⤷ Try a Trial | PRODUCT NAME: PRODUCT (I.E. ACTIVE INGREDIENT OR COMBINATION OF ACTIVE INGREDIENTS) FOR WHICH A CERTIFICATE IS REQUESTED: CRIZOTINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/12/793/001 EU/1/12/793/004 20121023 |
1786785 | CA 2013 00009 | Denmark | ⤷ Try a Trial | |
0763039 | 122008000023 | Germany | ⤷ Try a Trial | PRODUCT NAME: TEMSIROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/07/424/001 20071119 |
1786785 | C300587 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: CRIZOTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023 |
0536515 | 06C0031 | France | ⤷ Try a Trial | PRODUCT NAME: TIGECYCLINE; REGISTRATION NO/DATE: EU/01/06/336/001 20060424 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.